C4 Therapeutics (NASDAQ:CCCC) specializes in developing novel cancer treatments based on its cutting-edge technology platform aimed at degrading disease-causing proteins. By leveraging their proprietary TORPEDO platform, the company focuses on creating targeted therapies that have the potential to bring transformative outcomes in cancer care. Their projects span across various development stages, from discovery to clinical trials, aiming to tackle multiple types of cancer by disrupting the protein degradation pathway. The primary objective of C4 Therapeutics is to advance their pipeline of targeted oncology treatments, thereby offering new hope and options for patients grappling with cancer. Through rigorous research and development efforts, the company aspires to pioneer a new wave of oncology therapeutics that can effectively address unmet medical needs in the cancer treatment landscape.